Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 12:9:935977.
doi: 10.3389/fmed.2022.935977. eCollection 2022.

Effects of Normal Reference Range of Phosphorus and Corresponding PTH on Endothelial Function in CKD Patients

Affiliations

Effects of Normal Reference Range of Phosphorus and Corresponding PTH on Endothelial Function in CKD Patients

Shina Lee et al. Front Med (Lausanne). .

Abstract

Introduction: Endothelial dysfunction commonly occurs in chronic kidney disease (CKD) patients and increases the risk for cardiovascular disease. Among CKD patients, biomarkers involved in the pathogenesis of CKD-mineral bone disorder (CKD-MBD), such as phosphorus, parathyroid hormone, and fibroblast growth factor 23, are associated with endothelial dysfunction. We investigated whether these biomarkers induce endothelial dysfunction in CKD patients with normal phosphorus levels.

Methods: This cross-sectional study examined CKD patients with normal phosphorus levels; patients with an estimated glomerular filtration rate (eGFR) <15 or who were under dialysis were excluded. Iontophoresis with laser doppler flowmetry (ILDF) and peripheral arterial tonometry were performed to assess endothelial function in 85 patients. Pearson's correlation coefficient, multiple regression, and mediation analyses were performed to examine the association between CKD-MBD biomarkers and endothelial dysfunction.

Results: Endothelial dysfunction was observed in all subjects with a low response to ILDF and 27% of subjects according to peripheral arterial tonometry. Acetylcholine (Ach)-induced ILDF was significantly associated with eGFR (r = 0.22, P = 0.04), intact parathyroid hormone (iPTH; r = -0.46, P < 0.01), and VCAM-1 (r = -0.36, P < 0.01). The reactive hyperemia index (RHI) was significantly related to phosphorus levels (r = 0.32, P < 0.01) and iPTH (r = -0.39, P = 0.02). After adjusting for eGFR, iPTH and VCAM-1 remained independent factors for predicting endothelial dysfunction measured using Ach-induced ILDF. In addition, iPTH and phosphorus levels were independent predictors for endothelial dysfunction measured using RHI in the eGFR-adjusted model. Mediation analyses showed that the individual indirect effects of iPTH were significantly affected ILDF and RHI.

Conclusion: Serum levels of phosphorus and iPTH are associated with endothelial dysfunction, even in CKD patients with normal phosphorus levels.

Keywords: chronic kidney disease; endothelial function; fibroblast growth factor 23; parathyroid hormone; phosphorus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Scatter plot of the relationships between eGFR and iPTH; phosphorus (A), and Log FGF23; Log VCAM-1 (B). Phosphorus, iPTH, and Log VACM-1 were correlated with eGFR significantly (r = −0.32. p = 0.003 for phosphorus; r = −0.631, p < 0.001 for PTH; r = −0.405, p < 0.001 for Log VACM-1. There was no significant trend of Log FGF 23 in relation to eGFR (B).
Figure 2
Figure 2
(A–G) Mediation analyses of the associations between variables including eGFR, phosphorus, PTH, and endothelial dysfunction determined by EndoPAT and laser doppler iontophoresis. Path models and mediation analyses describe mediation of the association between variables and endothelial dysfunction through endothelial-related biomarkers individually. Path effects are reported as Odds-ratio scale of natural log-transformed values of biomarkers.

Similar articles

Cited by

References

    1. Chapter 3: Morbidity and mortality in patients with Ckd . Am J Kid Dis. (2017) 69:S67–92. 10.1053/j.ajkd.2017.01.012 - DOI
    1. Betriu A, Martinez-Alonso M, Arcidiacono MV, Cannata-Andia J, Pascual J, Valdivielso JM, et al. . Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the nefrona study. Nephrol Dia Transplant. (2014) 29:1415–22. 10.1093/ndt/gfu038 - DOI - PubMed
    1. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum Po4, Ca × Po4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. (2001) 12:2131–8. 10.1681/ASN.V12102131 - DOI - PubMed
    1. Achinger SG, Ayus JC. Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? J Am Soc Nephrol. (2006) 17(12 Suppl 3):S255–61 10.1681/ASN.2006080923 - DOI - PubMed
    1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. (1998) 31:607–17. 10.1053/ajkd.1998.v31.pm9531176 - DOI - PubMed